Mylan NV CEO Heather Bresch plans to defend the rising price of EpiPens when testifying before Congress Wednesday, sticking to the company’s effort to shift blame to health insurers and drug-benefit managers. Since scrutiny of EpiPen’s price intensified, the company has sought to point fingers at the other health-system actors that profit from rebates Mylan gives off the list price and that require some patients to pay high...

Source: Wall Street Journal September 21, 2016 14:08 UTC